Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Lancet
; 402(10411): 1449-1458, 2023 Oct 21.
Article
in En
| MEDLINE
| ID: mdl-37696275
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
Lancet
Year:
2023
Document type:
Article
Country of publication:
Reino Unido